IR@PKUHSC  > 北京大学第一临床医学院  > 肾脏内科
学科主题临床医学
Worldwide access to treatment for end-stage kidney disease: a systematic review
Liyanage, Thaminda1,2; Ninomiya, Toshiharu1; Jha, Vivekanand3,4,5; Neal, Bruce1; Patrice, Halle Marie6; Okpechi, Ikechi7; Zhao, Ming-hui8; Lv, Jicheng8; Garg, Amit X.9,10; Knight, John1; Rodgers, Anthony1; Gallagher, Martin1; Kotwal, Sradha1; Cass, Alan1,11; Perkovic, Vlado1,2
刊名LANCET
2015-05-16
DOI10.1016/S0140-6736(14)61601-9
385期:9981页:1975-1982
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]GLOBAL BURDEN ; RENAL-DISEASE ; CARE ; METAANALYSIS ; PROGRESSION ; DIALYSIS ; OUTCOMES ; FAILURE ; PROGRAM ; TRENDS
英文摘要

Background End-stage kidney disease is a leading cause of morbidity and mortality worldwide. Prevalence of the disease and worldwide use of renal replacement therapy (RRT) are expected to rise sharply in the next decade. We aimed to quantify estimates of this burden.

Methods We systematically searched Medline for observational studies and renal registries, and contacted national experts to obtain RRT prevalence data. We used Poisson regression to estimate the prevalence of RRT for countries without reported data. We estimated the gap between needed and actual RRT, and projected needs to 2030.

Findings In 2010, 2.618 million people received RRT worldwide. We estimated the number of patients needing RRT to be between 4.902 million (95% CI 4.438-5.431 million) in our conservative model and 9.701 million (8.544-11.021 million) in our high-estimate model, suggesting that at least 2.284 million people might have died prematurely because RRT could not be accessed. We noted the largest treatment gaps in low-income countries, particularly Asia (1.907 million people needing but not receiving RRT; conservative model) and Africa (432 000 people; conservative model). Worldwide use of RRT is projected to more than double to 5.439 million (3.899-7.640 million) people by 2030, with the most growth in Asia (0.968 million to a projected 2.162 million [1.571-3.014 million]).

Interpretation The large number of people receiving RRT and the substantial number without access to it show the need to both develop low-cost treatments and implement effective population-based prevention strategies.

语种英语
WOS记录号WOS:000354541700031
项目编号105255
资助机构Australian National Health and Medical Research Council Program Grant
引用统计
被引频次:217[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66703
专题北京大学第一临床医学院_肾脏内科
作者单位1.Royal N Shore Hosp, Sydney, NSW, Australia
2.George Inst Global Hlth, Splendor Forum, Jasola New Delhi, India
3.Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England
4.Univ Douala, Fac Med, Dept Clin Sci, Douala, Cameroon
5.Univ Sydney, George Inst Global Hlth, Sydney, NSW 2050, Australia
6.Postgrad Inst Med Educ & Res, Dept Nephrol, Chandigarh 160012, India
7.Univ Cape Town, Div Internal Med, ZA-7925 Cape Town, South Africa
8.Peking Univ, Dept Med, Div Renal, Hosp 1, Beijing 100871, Peoples R China
9.Univ Western Ontario, Dept Med, London, ON, Canada
10.Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada
11.Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia
推荐引用方式
GB/T 7714
Liyanage, Thaminda,Ninomiya, Toshiharu,Jha, Vivekanand,et al. Worldwide access to treatment for end-stage kidney disease: a systematic review[J]. LANCET,2015,385(9981):1975-1982.
APA Liyanage, Thaminda.,Ninomiya, Toshiharu.,Jha, Vivekanand.,Neal, Bruce.,Patrice, Halle Marie.,...&Perkovic, Vlado.(2015).Worldwide access to treatment for end-stage kidney disease: a systematic review.LANCET,385(9981),1975-1982.
MLA Liyanage, Thaminda,et al."Worldwide access to treatment for end-stage kidney disease: a systematic review".LANCET 385.9981(2015):1975-1982.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liyanage, Thaminda]的文章
[Ninomiya, Toshiharu]的文章
[Jha, Vivekanand]的文章
百度学术
百度学术中相似的文章
[Liyanage, Thaminda]的文章
[Ninomiya, Toshiharu]的文章
[Jha, Vivekanand]的文章
必应学术
必应学术中相似的文章
[Liyanage, Thaminda]的文章
[Ninomiya, Toshiharu]的文章
[Jha, Vivekanand]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。